|Lord Smith Prize, Pancreatic Society of Great Britain and Ireland.
|FRCS Gold Medal for best performance in the Intercollegiate General Surgery (HPB) FRCS exam.
|The Garden-Rees Prize for best oral paper in HPB at the National AUGIS meeting.
|American Association for Cancer Research (AACR) Pezcollar Scholar-in-Training award.
|Association for Radiation Research (ARR) commendation
|International Association of Surgical Gastroenterology and Oncology Award.
|Oxford School of Surgery Symposium Best Presentation (clinical section).
|Meyricke Graduate Scholarship Jesus College Oxford.
|The Hilda Margery Cuff prize for best senior medical student.
BMBS (Hons) BMedSc (Hons) Msc PGDip DPhil FRCS
NIHR Academic Clinical Lecturer
- Surgical Registrar, Health Education Thames Valley
My research aims to identify and test novel therapies for people suffering from pancreatic cancer. My work in the laboratory utilises high fidelity models of pancreatic cancer, allowing us to examine how tumours respond to different treatments. By identifying mechanisms of resistance, we can select therapeutic targets that render pancreatic cancer susceptible to conventional (radiotherapy) or novel (immune checkpoint inhibitors) treatments.
Recently, we discovered that a combination of short course radiotherapy (SBRT) combined with a drug that targets the immune system is effective at slowing tumour growth in a preclinical model of pancreas cancer. We continue to work with our collaborators to translate findings like these into clinical trials.
I also work with colleagues across Oxford on High Intensity Focused Ultrasound (HIFU). We are running a Phase I trial to determine the safety and feasibility of HIFU for treating locally advanced pancreatic cancer. We will draw on our experience from the laboratory to design future clinical trials that incorporate HIFU with immunotherapeutic strategies.
I graduated with Honours in Medicine at Nottingham University in 2011. My research career began with an Academic Foundation position supervised by Professor Jon Lund at the University of Nottingham. I was subsequently appointed as an NIHR Academic Clinical Fellow at the University of Oxford where I completed my basic surgical training. In 2015 I undertook a DPhil (PhD) in Oncology under the supervision of Professor Ruth Muschel at the CRUK/MRC Department of Oncology, University of Oxford. My thesis explored the tumour immune response to radiotherapy in preclinical models of colorectal and pancreatic adenocarcinoma. I took up my current position as a NIHR Clinical Lecturer at the Nuffield Department of Surgical Sciences in 2020. My current work focuses on therapeutic manipulation of the tumour microenvironment in pancreatic cancer. I also run early phase intervention trials through Oxford University Hospitals NHS Foundation Trust.
Immune checkpoint inhibition: a future guided by radiology.
Khan F. et al, (2023), Br J Radiol, 96
Ionizing Radiation Drives Key Regulators of Antigen Presentation and a Global Expansion of the Immunopeptidome.
Tailor A. et al, (2022), Mol Cell Proteomics, 21
The unique immune microenvironment of liver metastases: Challenges and opportunities.
Ciner AT. et al, (2021), Semin Cancer Biol, 71, 143 - 156
Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.
den Boer RB. et al, (2020), BJS Open, 4, 847 - 854
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
Philippou Y. et al, (2020), Br J Cancer, 123, 1089 - 1100